Ocular Therapeutix (OCUL) Earnings Preview: What to Expect on November 14th

Ocular Therapeutix (OCUL) is set to release its latest quarterly earnings report on Thursday, November 14th, 2024. Analysts anticipate an EPS of -$0.24, and investors are keenly awaiting news on whether the company will exceed estimates and provide favorable guidance for the upcoming quarter. This article delves into Ocular Therapeutix’s earnings history, analyst perspectives, peer comparisons, and a closer look at the company’s financial performance and market position.

LENZ Therapeutics’ LNZ100 Shows Strong Results in China Phase 3 Trial for Presbyopia

LENZ Therapeutics’ LNZ100, a potential treatment for presbyopia, continues to demonstrate strong efficacy and safety in a Phase 3 trial conducted in China. The drug met its primary and key secondary endpoints, showing statistically significant improvement in near vision for patients with presbyopia. These positive results, alongside the FDA’s recent acceptance of LENZ’s marketing application, bolster confidence in LNZ100’s potential approval and market success.

Scroll to Top